Camurus AB (publ) (0RD1)

Overview

Camurus AB (publ) is an innovator in the biopharmaceutical field, with a strong presence in Europe, Australia, the United States, and other international markets. Founded in 1991 and based in Lund, Sweden, the company specializes in developing and commercializing advanced medicinal treatments targeting severe and chronic conditions. Camurus operates as a pivotal player in the healthcare sector, demonstrating a robust commitment to improving patient outcomes through its therapeutic solutions. With strategic partnerships and licensing agreements bolstering its development and commercialization capabilities, the company is poised for continued growth and impact. Owned by Sandberg Development AB, Camurus stands at the forefront of addressing complex medical challenges with cutting-edge biopharmaceutical solutions.

Products and Services

• Buvidal: A pioneering buprenorphine injection formulated for the dual purposes of treating opioid dependence and managing chronic pain, offering a significant advancement in therapeutic options for patients grappling with these conditions.
• Brixadi: Dedicated to the treatment of opioid use disorder, Brixadi represents Camurus's commitment to combatting addiction and facilitating recovery through innovative medication solutions.
• CAM2038: Currently being investigated for its efficacy in treating chronic pain, offering a new hope for patients seeking long-term relief.
• CAM2029: In phase III clinical trials for acromegaly and neuroendocrine tumors, and in phase II for polycystic liver diseases, CAM2029 exemplifies the company’s focus on addressing rare and complex conditions with potential breakthrough therapies.
• CAM2043: Undergoing phase I clinical trial targeting pulmonary arterial hypertension, and in Phase II for treating Raynaud's phenomenon, underscoring Camurus's dedication to addressing cardiovascular and circulatory disorders.
• CAM2032: Presently in phase II clinical trials for prostate cancer treatment, CAM2032 highlights Camurus's investment in oncology and its commitment to advancing cancer care.
• CAM4072: Engaged in phase III clinical trials for genetic obesity disorders, showcasing the company's efforts in tackling complex obesity challenges through genetic insights and targeted treatments.
• CAM4071: In the early stage of clinical evaluation (phase I) for an endocrine disorder, embodying Camurus's exploratory approach to addressing endocrinological imbalances.
• CAM2047: In phase 1 clinical trial aimed at mitigating chemotherapy-induced nausea and vomiting, reflecting the company’s dedication to improving the quality of life for cancer patients undergoing treatment.

Through strategic collaborations, such as with Braeburn Pharmaceuticals for the development of CAM2038 for opioid use disorder, and with Rhythm Pharmaceuticals Inc. for CAM4072 targeting rare genetic disorders of obesity, Camurus is amplifying its impact. A licensing agreement with Solasia Pharma further extends its global reach, marking significant strides in the biopharmaceutical landscape.